The next evolution in this drug class involves inhibitors that only target mutated PI3K. This specificity aims to avoid effects on wild-type PI3K, which is involved in insulin signaling. The goal is to dramatically reduce severe side effects like hyperglycemia, which could allow for higher, more effective drug doses.

While known for weight loss, GLP-1 agonists are also highly effective for managing hyperglycemia from both steroids and PI3K inhibitors. Using low or "micro" doses can be very helpful in cancer patients, providing glucose control while minimizing GI side effects like nausea.

Advances in drug design mean newer PI3K inhibitors are more targeted, resulting in significantly less off-target toxicity. For example, some investigational agents have a hyperglycemia risk under 15%, a substantial improvement over earlier drugs, making them easier to manage clinically.

Hyperglycemia, a common side effect of the PI3K inhibitor Inavolycib, is directly linked to better patient outcomes. Patients with more hyperglycemia showed a stronger response (hazard ratio 0.38 vs. 0.51). This reframes a negative side effect as a potential biomarker of efficacy, urging physicians to manage it rather than discontinue treatment.

The Victoria 1 trial reported "historically low" discontinuation rates for the PI3K inhibitor alpelisib. This indicates that oncologists have become significantly better at proactively managing the drug's known toxicities, such as hyperglycemia. This real-world clinical maturation has improved the drug's tolerability and practical utility since its initial approval studies.

Clinicians are hesitant to use insulin for PI3K inhibitor-induced hyperglycemia. The primary concern is that exogenous insulin, a potent growth factor, could theoretically counteract the therapy's anti-tumor effect by promoting cancer cell survival, although this risk remains unproven.

iOnctura is tackling the PI3K Delta target, a mechanism with known efficacy but a history of severe side effects. By developing an allosteric modulator, they've engineered a drug (Roganolisib) with a significantly improved safety profile, aiming to unlock the target's full potential without its historical "baggage."

Second-generation PI3K inhibitor enovalisib has a 7% discontinuation rate compared to 25% for its predecessor, alpelisib. This is due to a better toxicity profile (e.g., 6% vs. 33% high-grade hyperglycemia) and improved proactive side effect management by clinicians.

While its IV administration is a hurdle, the pan-PI3K/mTOR inhibitor gedotolisib is clinically compelling because of its distinct safety profile. It causes significantly less hyperglycemia and diarrhea compared to oral PI3K inhibitors like alpelisib, making it an attractive option for patients where those specific toxicities are a major concern.